Karen Kozarsky, Ph.D., is Chief Scientific Officer and Co-Founder of SwanBio Therapeutics. She has 30 years of experience in gene therapy, with a primary focus on the development of gene therapy for inherited rare diseases utilizing adeno-associated virus (AAV) vectors. She has been involved in the development of multiple gene therapy products that are in clinical trials.
Previously, Dr. Kozarsky was President of Vector BioPartners, VP of R&D at REGENXBIO Inc., and Head, Gene Therapy in the GlaxoSmithKline Biopharm group. Prior to that, she worked in gene therapy at the University of Pennsylvania and at the University of Michigan. Dr. Kozarsky was named by the Alliance for Regenerative Medicine as the first co-Chair of the Gene Therapy Section to support policies to advance novel gene therapies and has been a committee member for the American Society of Gene & Cell Therapy. Dr. Kozarsky received a Ph.D. in Biology from MIT and a B.A. in Biology from Amherst College.